Search Results

. 22 Furthermore, single-institution retrospective trials magnify the risk of selection bias, making these results difficult for clinicians to apply to a given elderly patient. Role of Adjuvant Chemotherapy Adjuvant chemotherapy after resection

study by Neoptolemos et al, 3 adjuvant chemotherapy was linked to a significant surgical benefit in this setting, but adjuvant CRT had a “deleterious effect” on survival. “CRT after resection was not a good thing,” she added. However, Dr. Tempero noted

predictive factors? Can certain subsets of premenopausal women with ER-positive tumors be adequately treated using tamoxifen and/or ovarian suppression and forego adjuvant chemotherapy? What is the optimal strategy for using aromatase inhibitors (AIs) in the

. 5 Griggs JJ Culakova E Sorbero MF . Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens . J Clin Oncol 2007 : 25 : 2522 – 2527 . 6 Landercasper J Dietrich LL Johnson JM . A breast center

for recurrence. The TAILORx study was designed to validate the use of the test in patients with early-stage breast cancer at intermediate risk for recurrence. Based on its findings, 70% of these patients can safely avoid adjuvant chemotherapy. This

References 1 Levine MN Gafni A Markham B . A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer . Ann Intern Med 1992 ; 117 : 53 – 58 . 2 Whelan T. Levine M

Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations Expiration

reduced the local recurrence rate to 5% to 8% when combined with neoadjuvant chemoradiation and adjuvant chemotherapy. 5 , 6 Efforts to improve the current neoadjuvant standard of LARC through integrating newer chemotherapy or molecularly targeted agents

addition, the decision to administer adjuvant chemotherapy is determined based on comprehensive surgical staging. Patients with stage IA grade 1 to 2 and IB grade 1 to 2 cancers may undergo observation, whereas patients with stage I grade 3 or stage IC

neoadjuvant chemotherapy for patients with cT2, cT3, and cT4a bladder cancer without nodal disease and for adjuvant chemotherapy for patients with pT3 or pT4 disease or positive nodes (see cT2, Primary and Adjuvant Treatment [page 1242] and cT3, cT4a, Primary